Friday Sep 5, 2025
12-16.00 Arrival and registration
Session I Oncogenic Signalling networks
Chairs: Ruth Palmer and Janos Terzic
16.00-16.10 Welcome and introduction
16.10-16.40 Keynote Lecture: Joseph Schlessinger, Yale University, USA
“Developing kinase modulators for cancer therapeutics”
16.45-17:15 Keynote Lecture: Tony Hunter, SALK Institute, USA
“A journey from phosphotyrosine to phosphohistidine and beyond”
17.20-17.40 Letizia Lanzetti, Torino University, Italy
“Oncogenic trafficking”
17.45-18.05 EMBO Global Investigator Lecture: Wee Wei Tee, IMCB, Singapore
“Targeting transcriptional dysregulation in cancer: Insights from early
development”
18.10-18.30 Pier Paolo DiFiore, EIO, Italy
“Stemness in cancer”
19:00 – 23:00 Welcome Dinner
Saturday Sep 6, 2025
Session II Tumor Rewiring
Chairs: Ivan Dikic and Letizia Lanzetti
09.00-09.20 Serkan Kir, Koç University, Turkey
“EDA2R signaling in tumor-induced muscle wasting”
09.25-09.45 Sara Sigismund, IEO, Milan, Italy
“Endocytic control of cell plasticity in cancer”
09.50-10.10 Volker Dötsch, Goethe University Frankfurt, Germany
“Rewiring the p53 family in cancer”
10.15-10.35 Ruth Palmer, University of Gothenburg, Sweden
“The ALK-dependant metabolic landscape in neuroblastoma”
10.40 -11.10 Tea Break
11.10-11.30 René Bernards, NKI, Netherlands
“Combination therapies targeting RAS mutant tumors”
11.35-11.55 Mallika Singh, Revolution Medicine, USA
“Targeting Ras”
12.00-12.20 Krishna Rajalingam, Mainz University, Germany
“Targeting MYC and RAS -the two co-conspirators in cancer with flavagline
derivatives”
12.25-12.37 Selected talk: Markus Diefenbacher, Helmholtz Center Munich, Germany
“Targeting Ubiquitin Signaling vulnerabilities in KEAP1-Inactivated Lung
Cancer”
12.40-13.00 Flash talks (15)
13.00-13.20 Industry/Sponsor Talk – WuXi AppTec
13.00-15.30 Lunch break and free time
Session III Oncogenic Signaling and Genome Instability
Chairs: Wee Wei Tee and Marta Miaczynska
15.30-15.50 Ofer Shoshani, Weizmann, Israel
“Mechanisms and consequences of chromosome catastrophes in cancer”
15.55-16.15 Iva Tolić, RUĐER BOŠKOVIĆ Institute, Croatia
“Mechanobiology of mitosis and its role in mitotic fidelity”
16.20-16.40 Samuel Bakhoum, Geisel School of Medicine at Dartmouth, USA
“How chromosomal instability drives tumor progression”
16.45-17.05 Rene Medema, Princess Maxima Center, Netherlands
“Adaptation to genome instability”
17.10-17.40 Break
17.40-18.00 Ivan Dikic, Goethe University Frankfurt, Germany
“DNA-protein crosslinks,chromosome instability and liver cancer“
18.05-18.25 Geert Kops, Hubrecht Institute, Netherlands
“Chromosome segregation”
18.30-18.42 Selected talk: Stamatis Papathaasiou, Mainz University, Germany
“Mitotic errors as a source of inherited (epi)genetic instability”
18.45-18.55 EMBO Global Investigator Lecture: Dennis Kappei, CSI, Singapore
“Give me a break – how telomere-driven genomic instability contributes to
carcinogenesis”
Free for dinner and discussion
Sunday Sep 7, 2025
Session IV Cellular Plasticity in Cancer
Chairs: Krishnaraj Rajalingam and Johanna Ivaska
09.00-09.20 Maria Sibilia, Medical University of Vienna, Austria
“Microenvironmental drivers of inflammation and tumorigenesis: Modulating
innate immune cell signaling to enhance anti-cancer therapy”
09.25-09.45 Marta Miaczynska, IIMCB Warsaw, Poland
“Targeting AXL-dependent Trafficking and Signaling in Oncogenesis”
09.50-10.02 Selected talk: Sourav Banerjee, University of Dundee, UK
“An atypical, secreted kinase promotes the ‘seed and soil’ of high-grade brain
cancer”
10.05-10.17 Selected talk: Iván Plaza-Menacho, CNIO, Madrid, Spain
“The oncogenic CCDC6-RET fusion product is a dual ATP and ADP-dependent
kinase that functions via cis-autophosphorylation”
10.20-10.50 Tea Break
10.50-11.10 John Scott, University of Washington, USA
“AKAP signaling and tumor metastasis”
11.15-11.35 Roger Daly, Monash University, Australia
“Pseudokinases in Cancer”
11.40-11.52 Selected talk: Tiphaine Douanne, CNRS, Université de Nantes, France
“The LUBAC negatively regulates mitochondrial apoptosis and associated
inflammation”
11.55-12.20 Flash talks (15)
12.30-14.00 Lunch
14.00-16.00 Poster session I
16.30-23.00 Excursion to Dubrovnik and free time for dinner (bus returns at 22:00 and at 23:00)
Monday Sep 8, 2025
Session V Tumor Microenvironment and Metastasis
Chairs: Maria Sibilia and Dennis Kappei
09.00-09.20 Anwesha Dey, Genentech, USA
“Targeting the Hippo Pathway in Cancers”
09.25-09.45 Angel Lopez, SA Pathology, Australia
“How cytokine receptors specify cell fate in health and disease”
09.50-10.10 Colinda Scheele, VIB – KU Leuven, Belgium
“Intravital imaging and dynamics of tumour progression”
10.15-10.27 Selected talk: Michael Trpceski, Garvan Institute, Sydney, Australia
“Pinpointing and targeting novel drivers of pancreatic cancer progression and
metastasis using TRAP-seq”
10.30-11.00 Tea Break
11.00-11.20 Daniela Krause, Mainz University, Germany
“Targeting bone marrow microenvironment in leukemia”
11.25-11.45 Janos Terzic, University of Split, Croatia
“Gut microbiota carcinogen metabolism and tumor metastasis”
11.50-12.10 Johanna Ivaska, University of Turku, Finland
“Tumour-stroma crosstalk mediated regulation of drug sensitivity and
metastasis”
12.15-12.27 Selected talk: Anna Renzi, University of Trieste, Italy
“The Prolyl Isomerase Pin1 Mediates Immune Evasion in Fibrotic Breast
Cancer via Suppression of Transposable Elements”
12.30-12.45 Bernd Pulverer, EMBO Press, Germany
“From Bench to Journal: Connecting Open Science and Publishing”
13.00-14.30 Lunch
14.30-17.00 Poster session II
Session VI Therapy sensitivity and resistance
Chairs: Mallika Singh and Pier Paolo DiFiore
17.00-17.20 Mike Yaffe, MIT Center for Precision Cancer Medicine, USA
“CRISPR-Based Screening Reveals Mechanisms of Chemotherapy Sensitization
and Resistance in Glioblastoma and Ovarian Cancer”
17.25-17.45 Stuart Pitson, University of South Australia, Australia
“Therapy resistance mechanisms in myeloid cancers”
17.50-18.02 Selected talk: Matheus Henrique Dias, Princes Maxima Centrum, NL
“Therapeutic OVERactivation of oncogenic signaling as a cancer treatment
strategy”
18.05-18.17 Selected talk: Nenad Pavin, University of Zagreb, Croatia
“Macro-karyotype approach reveals a universal selection principle across
cancer types”
20.00 Farewell dinner
Tuesday Sep 9, 2025
Session VII Emerging therapeutics and diagnostics
Chairs: Rene Medema and Daniela Krause
09.30-09.50 Madelon Maurice, UMC Utrecht & Oncode Institute, NL
“SureTACs: targeting membrane protein degradation in cancer”
09.55-10.15 Paul Timpson, Garvan Institute, Australia
”Intravital imaging of pancreatic cancer response using live biosensors
imaging”
10.20-10:40 Jennie Lill, Genentech, USA
“Proteomics in drug discovery, development and clinical monitoring in
Oncology”
10.45-10:57 Tanmoy Mondal, University of Gothenburg, Sweden
“Epitranscriptomic Modifications in Neuroblastoma: A Promising New
Therapeutic Target”
11.00-11.30 Tea Break
11.30-11.50 Connie Jimenez, UMC-Cancer Center, Netherlands
“Phosphoproteomics for target discovery and treatment response prediction
in cancer”
11.55-12:07 Selected talk: Beatrice Tosoni, University of Padua, Italy
“QN-302: a novel G-quadruplex-binding molecule shows high efficacy against
liposarcoma”
12.10-12.30 Anguraj Sadanandam, ICR, UK
“Immune, Stromal and Metabolic Heterogeneity in Pancreatic Cancer and its
Impact on Therapeutic Responses”
12.30-13.00 Closing ceremony, poster awards and final remarks
Lunch and Departure